Thymoma
Thymoma is the tumor most strongly associated with myasthenia gravis (MG). Approximately 20-30% of patients with thymoma develop MG, and thymoma-associated MG (TAMG) represents roughly 15-20% of all MG patients 1.
Key Clinical Associations
The relationship between thymoma and MG is bidirectional and clinically significant:
- In thymoma patients: 20-30% develop MG, with an additional one-third possessing positive acetylcholine receptor (AChR) antibodies without clinical MG 1
- In MG patients: Thymoma is found in approximately 15-20% of cases, though this proportion has been decreasing over time 1
- Virtually all TAMG patients are seropositive for AChR antibodies 1
Clinical Implications
TAMG presents with more severe disease characteristics compared to non-thymoma MG:
- Disease is predominantly generalized rather than ocular 1
- More refractory to standard immunosuppressive treatment 1
- Patients with thymoma and MG have a favorable outcome due to earlier disease detection 2
Diagnostic Considerations
According to the most recent NCCN guidelines (2025), patients with thymoma should be evaluated clinically for signs of myasthenia gravis and other paraneoplastic syndromes with appropriate workup and treatment 3. This is explicitly stated as a footnote in the initial evaluation algorithm for mediastinal masses.
Imaging approach:
- Chest CT with contrast is the imaging modality of choice 1
- Thymoma typically appears as a well-defined round or oval mass in the thymus without lymph node enlargement 3
- MRI and PET scan may have ancillary roles in defining tumor invasiveness and staging 1
Management Priorities
Surgical resection should be considered for all patients with thymoma, regardless of MG status, as all thymomas are considered malignant 1. The 2022 clinical practice guideline emphasizes that total resection is preferred over partial resection 4.
Important caveats:
- New-onset MG can occur following thymectomy in patients with thymoma, and the presence of AChR antibodies preoperatively may be a predictive risk factor 1
- Preoperative optimization with IVIG or plasmapheresis is unnecessary in patients with stable MG 1
- Worsening myasthenic symptoms may herald a recurrence of thymoma 1
Risk Stratification
Thymoma subtype matters: Cortical and mixed thymomas show the strongest association with MG and are more likely to demonstrate capsular invasion and aggressive behavior 5. Among patients treated with pembrolizumab for thymic tumors, MG occurred in 42% of thymoma patients versus only 2% of thymic carcinoma patients 6.